Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases

Citations Over TimeTop 16% of 2010 papers

Related Papers

• → Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma(2021)11 cited
• → Selection of Patients with Hepatocellular Carcinoma for Sorafenib(2009)36 cited
• The up-regulation of P62 levels is associated with resistance of sorafenib in hepatocarcinoma cells.(2019)
• Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.(2014)
• → Μελέτη της επιδράσεως του αντιαγγειογενετικού παράγοντα sorafenib στην ηπατική αναγέννηση(2015)